Content deleted Content added
Updating report |
Updating report |
||
| (49 intermediate revisions by the same user not shown) | |||
Line 1:
{{User:SDZeroBot/NPP sorting/header|count=
{| class="wikitable sortable"
Line 10:
! scope="col" style="width: 4em;" | Notes
|-
| 2024-
| [[
| Samarium antimonide is a binary inorganic compound of [[samarium]] and [[antimony]] with the formula SmSb. It forms crystals.
| Stub
| data-sort-value=
| ▼
|-▼
| 2024-01-18
| [[Porous polymer]]
| Porous polymers are a class of [[porous media]] materials in which [[monomer]]s form [[2D polymer|2D]] and [[3D polymers]] containing angstrom- to nanometer-scale pores formed by the arrangement of the monomers. They may be either crystalline or amorphous. Subclasses include [[covalent organic framework]]s (COFs), [[hydrogen-bonded organic framework]]s (HOFs), [[metal-organic framework]]s (MOFs), and [[porous organic polymer]]s (POPs).
| Start
| data-sort-value=
|
|-
| 2024-
| [[
| Praseodymium monoselenide is a compound with the chemical formula PrSe. It forms crystals.
| Stub
| data-sort-value=
|
|-
|
| [[
| Iron(III) selenite is an inorganic compound with the chemical formula Fe<sub>2</sub>(SeO<sub>3</sub>)<sub>3</sub>. It exists anhydrous form and as various hydrates. The heptahydrate is produced by the reaction of [[ferric chloride]] and [[selenous acid]] (or [[sodium selenite]]) at a pH of 1.05.
| Start
| data-sort-value=
▲|
▲|-
| 2025-05-23▼
| C▼
▲| data-sort-value=37 | [[Special:Contribs/Хокус Покус 333|Хокус Покус 333]] (37)
|
|-
|
| [[Fudosteine]] <small>(Chemical compound)</small>
| Fudosteine (Cleanal) is a [[mucolytic agent]]. In Japan, it is approved for the treatment of [[bronchial asthma]], [[chronic bronchitis]], [[pulmonary emphysema]], [[bronchiectasis]], [[pulmonary tuberculosis]], [[pneumoconiosis]], atypical [[mycobacterial disease]], and [[diffuse panbronchiolitis]].
| Stub
| data-sort-value=
|
|-
Line 52:
|
|-
| 2025-
| [[
| <sup>177</sup>Lu-NNS309 is an investigational radiopharmaceutical compound currently under development by Novartis Pharmaceuticals for the treatment of various [[Neoplasm|solid tumors]]. The compound is being evaluated in Phase I clinical trials for patients with pancreatic, lung, breast, and colorectal cancers.▼
| C
| data-sort-value=
|
|-
Line 63:
| OpRegen (also known as RG6501) is an investigational allogeneic cell therapy developed by Lineage Cell Therapeutics for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). The therapy consists of human retinal pigment epithelial (RPE) cells administered via subretinal injection as a single treatment.
| C
| data-sort-value=
|
|-
| 2025-
| [[
| Fluorescence upconversion (FU) is an [[Ultrafast laser spectroscopy|ultrafast laser spectroscopic]] technique. It is a variant of [[sum-frequency generation]] (of which the [[second-harmonic generation]] (SHG) is a special case) but applied to the detection of the incoherent [[fluorescence]]. It is therefore closely related to the [[Optical Kerr Gating]] (OKG) technique.
▲| <sup>177</sup>Lu-NNS309 is an investigational radiopharmaceutical compound currently under development by Novartis Pharmaceuticals for the treatment of various [[Neoplasm|solid tumors]]. The compound is being evaluated in Phase I clinical trials for patients with pancreatic, lung, breast, and colorectal cancers.
| C
| data-sort-value=
|
|-
|
| [[
| Jens Bruun de Neergaard (14 June 1742 – 22 April 1788) was a [[Denmark|Danish]] judge and landowner. He owned [[Svenstrup (manor house)|Svenstrup Manor]], at [[Borup, Køge|Broup]], [[Køge Municipality]], whouse present main building he constructed in the 1780s. On 31 May 1780, alongside his younger brother, Johan Thomas de Neergaard (1745–1806), he was ennobled by [[letters patent]].
|
| data-sort-value=
|
|-
| 2025-
| [[Hellenic Championship (Tennis)]] <small>(Tennis tournament)</small>
| The Hellenic Championship is an [[ATP 250 tournaments|ATP 250 tournament]] held in [[Athens]], [[Greece]]. The event is played on indoor [[hardcourt]] at the [[OAKA Basketball Arena]], a multi-purpose venue that was used for the [[2004 Summer Olympics]]. It replaces the [[Belgrade Open]] on the calendar and it is scheduled to debut in November 2025.
|
| data-sort-value=
|
|-
| 2025-08-
| [[Structural Dynamics Response Assay]] <small>(Biochemical analysis procedure)</small>
| The structural dynamics response (SDR) assay is a type of [[biophysical]] test used to measure [[ligand binding]] to a target [[protein]]. The assay is configured as a simple mix and read format that can be conducted in very low volumes, therefore suitable for [[drug discovery]] applications such as [[high throughput screening]] (HTS), or in the development of a drug candidate during [[medicinal chemistry]] optimization cycles.
| Start
| data-sort-value=
|
|-
| 2025-06-16
| [[Sefaxersen]] <small>(Antisense oligonucleotide therapy under development)</small>
| Sefaxersen (also known as RO7434656, RG6299, ISIS-696844 and IONIS-FB-LRx) is an investigational [[antisense oligonucleotide]] (ASO) drug developed by [[Roche Holding AG]] in partnership with [[Ionis Pharmaceuticals]]. It targets [[complement factor B]] (CFB) to treat [[complement system]]-mediated diseases, primarily [[IgA nephropathy]] (IgAN) and [[geographic atrophy]] (GA) secondary to [[age-related macular degeneration]].
▲| C
| data-sort-value=5704 | [[Special:Contribs/Noxoug1|Noxoug1]] (5704)
|
|-
| 2025-08-31
| [[Maurizio Cignitti]]
| Maurizio Cignitti (Rome, 24 July 1930 – Rome, 10 January 2017) was an Italian chemist and researcher, known for his work in theoretical chemistry, medicinal chemistry, and biologically relevant molecular interactions. He held prominent positions at the Istituto Superiore di Sanità (Italian National Institute of Health) and contributed to major international negotiations on ozone layer depletion and to the harmonization of European pharmacopeias.
| C
| data-sort-value=22 | [[Special:Contribs/Piman61|Piman61]] (22)
|
|-
| [[Erythrocyte-based drug delivery]] <small>(Drug delivery method)</small>
| Erythrocyte-based drug delivery systems (EBDDS) use [[red blood cells]], their membranes, or their components to release and deliver pharmaceutical agents throughout the body in a controlled manner. Because red blood cells circulate for long periods of time and are potentially non-[[immunogenic]], they are an attractive vector for [[drug delivery]] via the circulatory system.
| C
| data-sort-value=6 | [[Special:Contribs/DrugDelivery2025|DrugDelivery2025]] (6)
|
|-
| 2025-07-31
| [[Vatinoxan]] <small>(Pharmaceutical compound)</small>
| Vatinoxan, originally known as MK-467, is an [[Alpha-2_adrenergic_receptor#Antagonists|α<sub>2</sub>-adrenergic receptor antagonist]] used in veterinary medicine alongside [[Alpha-2_adrenergic_receptor#Agonists|α<sub>2</sub>-adrenergic receptor agonists]] to counteract [[vasoconstriction]] and [[hypertension]] while maintaining sedation. Vatinoxan does not cross the [[blood–brain barrier]] giving it a unique pharmacological profile compared to the other α<sub>2</sub>-adrenergic receptor antagonists and distinct clinical application.
| C
| data-sort-value=499 | [[Special:Contribs/Sacristy|Sacristy]] (499)
|
|}
<span style="font-style: italic; font-size: 85%;">Last updated by [[User:SDZeroBot|SDZeroBot]] <sup>''[[User:SD0001|operator]] / [[User talk:SD0001|talk]]''</sup> at 13:
| |||